Clinical applications of positron emission tomography in sarcoma management

References

• Plathow C, Weber WA. Tumor cell metabolism imaging. J. Nucl. Med.49(Suppl. 2), 43S–63S (2008).
   PubMed Web of Science ®Google Scholar
• Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer2(9), 683–693 (2002).
   PubMed Web of Science ®Google Scholar
• Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev.27(4), 545–554 (2008).
   PubMed Web of Science ®Google Scholar
• Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol.22(5), 360–371 (1987).
   PubMed Web of Science ®Google Scholar
• Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology164(2), 521–526 (1987).
   PubMed Web of Science ®Google Scholar
• Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur. J. Nucl. Med. Mol. Imaging37(7), 1408–1425 (2009).
   PubMed Web of Science ®Google Scholar
• Kern KA, Brunetti A, Norton JA et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J. Nucl. Med.29(2), 181–186 (1988).
   PubMed Web of Science ®Google Scholar
• Schulte M, Brecht-Krauss D, Heymer B et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J. Nucl. Med.41(10), 1695–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Schulte M, Brecht-Krauss D, Heymer B et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur. J. Nucl. Med.26(6), 599–605 (1999).
   PubMedGoogle Scholar
• Adler LP, Blair HF, Makley JT et al. Noninvasive grading of musculoskeletal tumors using PET. J. Nucl. Med.32(8), 1508–1512 (1991).
   PubMed Web of Science ®Google Scholar
• Nieweg OE, Pruim J, van Ginkel RJ et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J. Nucl. Med.37(2), 257–261 (1996).
   PubMedGoogle Scholar
• Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur. J. Nucl. Med. Mol. Imaging33(11), 1290–1295 (2006).
   PubMed Web of Science ®Google Scholar
• Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging33(6), 683–691 (2006).
   PubMed Web of Science ®Google Scholar
• Punt SE, Eary JF, O’Sullivan J, Conrad EU. Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics. Nucl. Med. Commun.30(7), 546–549 (2009).
   PubMed Web of Science ®Google Scholar
• Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann. Surg.231(3), 380–386 (2000).
   PubMed Web of Science ®Google Scholar
• Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur. J. Nucl. Med. Mol. Imaging DOI: 10.1007/s00259-009-1203-0 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Hicks RJ. Functional imaging techniques for evaluation of sarcomas. Cancer Imaging5(1), 58–65 (2005).
   PubMedGoogle Scholar
• Jager PL, Hoekstra HJ, Leeuw J, van der Graaf WT, de Vries EG, Piers D. Routine bone scintigraphy in primary staging of soft tissue sarcoma: is it worthwhile? Cancer89(8), 1726–1731 (2000).
   PubMed Web of Science ®Google Scholar
• Tateishi U, Hosono A, Makimoto A et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann. Nucl. Med.23(2), 155–161 (2009).
   PubMed Web of Science ®Google Scholar
• Mody RJ, Bui C, Hutchinson RJ et al. FDG PET imaging of childhood sarcomas. Pediatr. Blood Cancer54(2), 222–227 (2010).
   PubMed Web of Science ®Google Scholar
• Volker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J. Clin. Oncol.25(34), 5435–5441 (2007).
   PubMed Web of Science ®Google Scholar
• Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J. Nucl. Med.48(12), 1932–1939 (2007).
   PubMed Web of Science ®Google Scholar
• Piperkova E, Mikhaeil M, Mousavi A et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin. Nucl. Med.34(3), 146–150 (2009).
   PubMed Web of Science ®Google Scholar
• Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur. J. Nucl. Med.27(9), 1305–1311 (2000).
   PubMedGoogle Scholar
• Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann. Oncol.12(4), 479–486 (2001).
   PubMed Web of Science ®Google Scholar
• Iagaru A, Chawla S, Menendez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl. Med. Commun.27(10), 795–802 (2006).
   PubMed Web of Science ®Google Scholar
• Pisters PW, Patel SR, Varma DG et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J. Clin. Oncol.15(12), 3481–3487 (1997).
   PubMed Web of Science ®Google Scholar
• DeLaney TF, Spiro IJ, Suit HD et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys.56(4), 1117–1127 (2003).
   PubMed Web of Science ®Google Scholar
• Kraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J. Clin. Oncol.24(4), 619–625 (2006).
   PubMed Web of Science ®Google Scholar
• Benz MR, Czernin J, Allen-Auerbach MS et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin. Cancer Res.15(8), 2856–2863 (2009).
   PubMed Web of Science ®Google Scholar
• Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J. Nucl. Med.48(Suppl. 1), 36S–44S (2007).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg.231(1), 51–58 (2000).
   PubMed Web of Science ®Google Scholar
• Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br. J. Surg.90(10), 1178–1186 (2003).
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med.347(7), 472–480 (2002).
   PubMed Web of Science ®Google Scholar
• Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist13(Suppl. 2), 4–7 (2008).
   PubMed Web of Science ®Google Scholar
• Stroobants S, Goeminne J, Seegers M et al.18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer39(14), 2012–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Antoch G, Kanja J, Bauer S et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J. Nucl. Med.45(3), 357–365 (2004).
   PubMed Web of Science ®Google Scholar
• Gayed I, Vu T, Iyer R et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med.45(1), 17–21 (2004).
   PubMed Web of Science ®Google Scholar
• Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl. Med. Commun.25(5), 433–438 (2004).
   PubMed Web of Science ®Google Scholar
• Van den Abbeele AD. The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist13(Suppl. 2), 8–13 (2008).
   PubMed Web of Science ®Google Scholar
• Holdsworth CH, Badawi RD, Manola JB et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am. J. Roentgenol.189(6), W324–W330 (2007).
   PubMed Web of Science ®Google Scholar
• Prior JO, Montemurro M, Orcurto MV et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J. Clin. Oncol.27(3), 439–445 (2009).
   PubMed Web of Science ®Google Scholar
• Evilevitch V, Weber WA, Tap WD et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin. Cancer Res.14(3), 715–720 (2008).
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer103(2), 339–348 (2005).
   PubMed Web of Science ®Google Scholar
• Cheon GJ, Kim MS, Lee JA et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J. Nucl. Med.50(9), 1435–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Costelloe CM, Macapinlac HA, Madewell JE et al.18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J. Nucl. Med.50(3), 340–347 (2009).
   PubMed Web of Science ®Google Scholar
• Hamada K, Tomita Y, Inoue A et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann. Nucl. Med.23(1), 89–95 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer94(12), 3277–3284 (2002).
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J. Nucl. Med.51(4), 551–558 (2010).
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer35(13), 1773–1782 (1999).
   PubMed Web of Science ®Google Scholar
• Shankar LK, Hoffman JM, Bacharach S et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J. Nucl. Med.47(6), 1059–1066 (2006).
   PubMed Web of Science ®Google Scholar
• Arush MW, Israel O, Postovsky S et al. Positron emission tomography/computed tomography with 18Fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr. Blood Cancer49(7), 901–905 (2007).
   PubMed Web of Science ®Google Scholar
• Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann. Oncol.13(1), 157–160 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin. Nucl. Med.28(10), 815–820 (2003).
   PubMed Web of Science ®Google Scholar
• Kole AC, Nieweg OE, van Ginkel RJ et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann. Surg. Oncol.4(1), 57–63 (1997).
   PubMed Web of Science ®Google Scholar
• Park JY, Kim EN, Kim DY et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol. Oncol.109(2), 255–262 (2008).
   PubMed Web of Science ®Google Scholar
• Kneisl JS, Patt JC, Johnson JC, Zuger JH. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin. Orthop. Relat. Res.450, 101–104 (2006).
   PubMedGoogle Scholar
• Postovsky S, Barzilai M, Meller I, Kollander Y, Futerman B, Ben Arush MW. Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience. J. Pediatr. Hematol. Oncol.30(3), 189–195 (2008).
   PubMed Web of Science ®Google Scholar
• Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur. J. Nucl. Med. Mol. Imaging31(2), 189–195 (2004).
   PubMed Web of Science ®Google Scholar
• Lisle JW, Eary JF, O’Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin. Orthop. Relat. Res.467(6), 1605–1611 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Schuetze SM, Butrynski JE et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol.23(34), 8828–8834 (2005).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF. [F-18]-fluorodeoxy-d-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer115(15), 3519–3525 (2009).
   PubMed Web of Science ®Google Scholar
• Eary JF, O’Sullivan F, O’Sullivan J, Conrad EU. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J. Nucl. Med.49(12), 1973–1979 (2008).
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med.50(Suppl. 1), 122S–150S (2009).
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer38(4), 543–549 (2002).
   PubMed Web of Science ®Google Scholar
• Buck AK, Herrmann K, Buschenfelde CM et al. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin. Cancer Res.14(10), 2970–2977 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer JS, Nadel HR, Marina N et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr. Blood Cancer51(2), 163–170 (2008).
   PubMed Web of Science ®Google Scholar
• Fahey FH. Dosimetry of pediatric PET/CT. J. Nucl. Med.50(9), 1483–1491 (2009).
   PubMed Web of Science ®Google Scholar